Casey M. Tansey
Casey M. Tansey's purchase track record
Casey M. Tansey has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/13/2026 | MOBI | $996K | pending | pending | — |
| 5/11/2026 | MOBI | $1000K | +6.1% | pending | — |
| 8/1/2025 | SI | $600K | -17.8% | -0.6% | +11.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Mobia Medical Announces Q3 2026 Earnings Release Date. Mobia Medical Inc. has set November 5, 2026 as the date to release its third‑quarter 2026 financial results. The announcement comes as the company prepares to share its latest performance data. Investors will be able to see how the company’s operations and revenue compare to expectations. The disclosure follows the company’s recent trading near its 52‑week range.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays Starts Coverage of Inspire Medical with Underweight. Barclays has begun coverage of Inspire Medical Systems and assigned an Underweight rating. The firm set a price target of $65 for the stock. This rating follows the recent analyst activity on the company. The stock is currently near its long‑term support level.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Heartflow featured in AI healthcare stock roundup. Heartflow was included in a recent Yahoo Finance article highlighting top AI healthcare stocks alongside Pfizer and another company. This mention places the firm in the conversation regarding artificial intelligence applications in the medical sector. The stock currently trades within its 52-week range, with analysts maintaining an average price target of $46.00.
Transaction History
| SI | ▲ Buy | Grant | 733 | $14K | 10/5/2026 | View on chart |
| MOBI | ▲ Buy | Open Market | 16,441 | $199K | 8/18/2026 | View on chart |
| MOBI | ▲ Buy | Open Market | 17,166 | $203K | 8/17/2026 | View on chart |
| MOBI | ▲ Buy | Open Market | 15,721 | $183K | 8/14/2026 | View on chart |
| MOBI | ▲ Buy | Open Market | 100 | $1K | 8/14/2026 | View on chart |
| MOBI | ▲ Buy | Open Market | 35,572 | $409K | 8/13/2026 | View on chart |
| INSP | ▲ Buy | Grant | 346 | $0 | 7/15/2026 | View on chart |
| SI | ▲ Buy | Grant | 5,046 | $0 | 6/26/2026 | View on chart |
| MOBI | ▼ Sell | Other | 166,666 | — | 5/11/2026 | View on chart |
| MOBI | ▲ Buy | Open Market | 66,666 | $1000K | 5/11/2026 | View on chart |
| MOBI | ▼ Sell | Other | 314,090 | — | 5/11/2026 | View on chart |
| MOBI | ▼ Sell | Other | 3,312,736 | — | 5/11/2026 | View on chart |
| INSP | ▲ Buy | Grant | 3,562 | $0 | 4/30/2026 | View on chart |
| INSP | ▲ Buy | Grant | 308 | $16K | 4/15/2026 | View on chart |
| INSP | ▲ Buy | Grant | 181 | $17K | 1/15/2026 | View on chart |
| INSP | ▲ Buy | Grant | 221 | $17K | 10/14/2025 | View on chart |
| HTFL | ▼ Sell | Other | 3,072,759 | — | 8/11/2025 | View on chart |
| HTFL | ▼ Sell | Other | 98,303 | — | 8/11/2025 | View on chart |
| HTFL | ▼ Sell | Other | 16,447 | — | 8/11/2025 | View on chart |
| SI | ▼ Sell | Other | 1,686,403 | — | 8/1/2025 | View on chart |
| SI | ▼ Sell | Other | 85,587 | — | 8/1/2025 | View on chart |
| SI | ▼ Sell | Other | 921,131 | — | 8/1/2025 | View on chart |
| SI | ▲ Buy | Grant | 7,666 | $0 | 8/1/2025 | View on chart |
| SI | ▲ Buy | Open Market | 40,000 | $600K | 8/1/2025 | View on chart |
| INSP | ▲ Buy | Grant | 133 | $17K | 7/15/2025 | View on chart |
| INSP | ▲ Buy | Grant | 1,266 | $0 | 5/1/2025 | View on chart |
| INSP | ▲ Buy | Grant | 103 | $15K | 4/14/2025 | View on chart |
| INSP | ▲ Buy | Grant | 81 | $14K | 1/15/2025 | View on chart |
| INSP | ▲ Buy | Grant | 68 | $14K | 10/14/2024 | View on chart |
| INSP | ▲ Buy | Grant | 103 | $14K | 7/15/2024 | View on chart |
| INSP | ▲ Buy | Grant | 716 | $0 | 5/2/2024 | View on chart |
| INSP | ▲ Buy | Grant | 62 | $14K | 4/12/2024 | View on chart |
| INSP | ▲ Buy | Grant | 2 | $652 | 1/16/2024 | View on chart |
| INSP | ▲ Buy | Grant | 8 | $1K | 1/16/2024 | View on chart |
| INSP | ▲ Buy | Grant | 77 | $14K | 1/16/2024 | View on chart |
| INSP | ▲ Buy | Grant | 87 | $13K | 10/13/2023 | View on chart |
| INSP | ▼ Sell | Gift | 500 | $0 | 8/25/2023 | View on chart |
| INSP | ▼ Sell | Gift | 500 | $0 | 8/25/2023 | View on chart |
| INSP | ▼ Sell | Gift | 500 | $0 | 8/25/2023 | View on chart |
| INSP | ▼ Sell | Gift | 500 | $0 | 8/25/2023 | View on chart |
| INSP | ▲ Buy | Grant | 40 | $13K | 7/17/2023 | View on chart |
| INSP | ▲ Buy | Grant | 669 | $0 | 4/27/2023 | View on chart |
| INSP | ▲ Buy | Grant | 56 | $13K | 4/10/2023 | View on chart |
| INSP | ▲ Buy | Grant | 52 | $13K | 1/10/2023 | View on chart |
| INSP | ▲ Buy | Grant | 81 | $14K | 10/11/2022 | View on chart |
| INSP | ▲ Buy | Grant | 77 | $15K | 7/11/2022 | View on chart |
| INSP | ▲ Buy | Grant | 59 | $15K | 4/8/2022 | View on chart |
| INSP | ▲ Buy | Grant | 65 | $15K | 1/10/2022 | View on chart |
| INSP | ▲ Buy | Grant | 64 | $15K | 10/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Shoulder Innovations Q2 2026 earnings and BTIG target raise
Shoulder Innovations held its Q2 2026 earnings conference call, where management discussed the quarter’s results. BTIG analyst kept its rating on the stock and increased the price target to $27. The new target is above the current average analyst estimate of $26.25 and above the 52‑week high of $24.59.
Shoulder Innovations Q2 2026 earnings and BTIG target raise. Shoulder Innovations held its Q2 2026 earnings conference call, where management discussed the quarter’s results. BTIG analyst kept its rating on the stock and increased the price target to $27. The new target is above the current average analyst estimate of $26.25 and above the 52‑week high of $24.59.